1. Scrip
  2. >>Business
  3. >>Strategy

AbbVie Defends Humira With Aggressive Discount In First EU Tender

 
• By Jo Shorthouse

AbbVie has reportedly slashed the price of its TNF inhibitor Humira by 80% in the first European tender for biosimilar adalimumab, far beyond the 50% discount previously thought.

Brown bear
AbbVie has laid down its defense of Humira's European market • Source: Shutterstock

AbbVie Inc. is ready for a fight to keep rivals away from having their piece of the biosimilar adalimumab market if reports of a price cut of 80% are anything to go by.

The discount in an, as yet, unknown market, is not expected to hurt AbbVie much financially

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.